<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112444477</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112444477</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lin</surname>
<given-names>R</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
<xref ref-type="corresp" rid="corresp1-0960327112444477"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mao</surname>
<given-names>Y</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112444477">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bu</surname>
<given-names>X</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112444477">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ji</surname>
<given-names>Q</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhai</surname>
<given-names>X</given-names>
</name>
<xref ref-type="aff" rid="aff2-0960327112444477">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>L</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>K</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112444477">1</xref>
</contrib>
<aff id="aff1-0960327112444477">
<label>1</label>Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, PR China</aff>
<aff id="aff2-0960327112444477">
<label>2</label>Shaanxi’s Tiansen Drug Research and Development Limited Company, Xi’an, Shaanxi, PR China</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327112444477">Rong Lin, Department of Pharmacology, Key Laboratory of Environment and Genes Related to Diseases, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, PR China Email: <email>linrong63@yahoo.com.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>11</issue>
<fpage>1092</fpage>
<lpage>1101</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Divalproex sodium is an antiepileptic drug. Hepatotoxicity is one of the most common side effects induced by divalproex sodium. Impaired fatty acid metabolism is considered to play an important role in the drug-induced hepatotoxicity. The sterol regulatory element-binding protein 1c (SREBP-1c) and peroxisome proliferator-activated receptor α (PPARα) are two key transcription factors involved, respectively, in fatty acid synthesis and degradation in liver. In the present study, we investigated the hepatotoxicity induced by divalproex sodium and its potential mechanism. The results indicated that divalproex sodium significantly decreased the cell viability and increased lactate dehydrogenase leakage in hepatocytes. The activities of alanine aminotransferase and aspartate transaminase were increased in hepatocytes treated with divalproex sodium. Furthermore, divalproex sodium activated SREBP-1c and increased the mRNA expressions of acetyl-CoA carboxylase 1, fatty acid synthase and stearoyl-CoA desaturase 1. Divalproex sodium also inhibited PPARα and decreased the messenger RNA expressions of 3-hydroxy-3-methylglutaryl-CoA synthase 2 and carnitine palmitoyltransferase 1A. These results suggest that the hepatotoxicity induced by divalproex sodium may be related with fatty acid synthesis and degradation mediated by SREBP-1c and PPARα in hepatocytes.</p>
</abstract>
<kwd-group>
<kwd>Divalproex sodium</kwd>
<kwd>hepatotoxicity</kwd>
<kwd>fatty acid metabolism</kwd>
<kwd>SREBP-1c</kwd>
<kwd>PPARα</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112444477">
<title>Introduction</title>
<p>Divalproex sodium is an antiepileptic drug. It is also used to treat mania and to help prevent migraine headaches.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112444477">1</xref>
</sup> Since its introduction in the market, divalproex sodium showed some side effects that have been reported in the clinic.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112444477">2</xref>,<xref ref-type="bibr" rid="bibr3-0960327112444477">3</xref>
</sup> Hepatotoxicity is one of the most serious side effects induced by divalproex sodium, especially in children younger than 2 years old.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112444477">4</xref>
</sup> However, the mechanism of hepatotoxicity induced by divalproex sodium is not clear. So the present study focused on divalproex sodium–induced hepatotoxicity and its potential mechanism.</p>
<p>Impaired fatty acid metabolism is considered to play an important role in the drug-induced hepatotoxicity.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112444477">5</xref>
</sup> Divalproex sodium is composed of sodium valproate and valproic acid.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112444477">2</xref>
</sup> Our previous study has revealed that sodium valproate induced hepatotoxicity by elevating the gene expressions of cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and ATP binding cassette transporter G1 (ABCG1) related to fatty acid metabolism.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112444477">6</xref>
</sup> However, the effects of divalproex sodium on other gene expressions related to fatty acid metabolism in hepatocytes have not been elucidated yet. It has been reported that there are mainly two groups of transcription factors that mediate fatty acid metabolism in liver: the sterol regulatory element–binding proteins (SREBPs) and peroxisome proliferator–activated receptors (PPARs).<sup>
<xref ref-type="bibr" rid="bibr7-0960327112444477">7</xref>
</sup> The mammalian genome encodes three SREBP isoforms, designated SREBP-1a, SREBP-1c and SREBP-2. The SREBP-1c participates in fatty acid synthesis by activating several enzymes including acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1).<sup>
<xref ref-type="bibr" rid="bibr8-0960327112444477">8</xref>,<xref ref-type="bibr" rid="bibr9-0960327112444477">9</xref>
</sup> SREBP-1c is involved in fatty acid synthesis, and the inhibition of PPARα function leads to impaired fatty acid degradation. PPARα has been proven to activate the genes including 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) and carnitine palmitoyltransferase 1A (CPT1A), thereby improving fatty acid degradation.<sup>
<xref ref-type="bibr" rid="bibr10-0960327112444477">10</xref>
</sup> Interestingly, the SREBP-1c is reported to interact and cross-talk with PPARα.<sup>
<xref ref-type="bibr" rid="bibr11-0960327112444477">11</xref>,<xref ref-type="bibr" rid="bibr12-0960327112444477">12</xref>
</sup> It has been reported that antipsychotic drugs including clozapine, olanzapine and haloperidol not only increased the expressions of SREBP-1c and its downstream genes ACC1, FAS and SCD1 but also decreased the expressions of PPARα and its downstream gene CPT1A in hepatocytes.<sup>
<xref ref-type="bibr" rid="bibr13-0960327112444477">13</xref>,<xref ref-type="bibr" rid="bibr14-0960327112444477">14</xref>
</sup> On the contrary, the study indicated that the hepatotoxicity induced by Fumonisin B1 was independent of PPARα.<sup>
<xref ref-type="bibr" rid="bibr15-0960327112444477">15</xref>
</sup> Clofibrate causes an upregulation of PPARα target genes but does not alter the expression of SREBP target genes in the liver of pigs.<sup>
<xref ref-type="bibr" rid="bibr16-0960327112444477">16</xref>
</sup>
</p>
<p>In the present study, the hepatotoxicity induced by divalproex sodium was assessed by measuring the cell viability, lactate dehydrogenase (LDH) leakage and the activities of alanine aminotransferase (ALT) and aspartate transaminase (AST) in hepatocytes. Then the messenger RNA (mRNA) expressions of SREBP-1c, ACC1, FAS, SCD1, PPARα, HMGCS2 and CPT1A were determined in hepatocytes treated with divalproex sodium.</p>
</sec>
<sec id="section2-0960327112444477" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-0960327112444477">
<title>Materials</title>
<p>Dulbecco’s modified eagle’s medium (DMEM) and fetal bovine serum (FBS) were provided by Hyclone (Logan, Utah, USA). Collagenase B was purchased from Roche (Basel, Switzerland). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and dimethyl sulfoxide (DMSO) were purchased from Amersco (Solon, Ohio, USA). Other reagents were of the highest grade commercially available. All those primers were purchased from Applied Biosystems Company (California, USA).</p>
</sec>
<sec id="section4-0960327112444477">
<title>Preparation of divalproex sodium</title>
<p>Divalproex sodium was synthetized by Tiansen Bioengineering and Technology Limited Company of Shaanxi in China. Divalproex sodium was prepared according to the procedures described below.<sup>
<xref ref-type="bibr" rid="bibr17-0960327112444477">17</xref>,<xref ref-type="bibr" rid="bibr18-0960327112444477">18</xref>
</sup>
</p>
<p>In 100 ml of acetone 16.6 g of sodium valproate and 14.4 g of valproic acid are dissolved at about 50°C. The solution is cooled to about 0°C for 5 h, filtered and the crystalline precipitate washed with 10 ml precooled acetone at about 0°C. Then 26.4 g white crystalline powder was obtained, which melts at 98.6–99.7°C. The new compound obtained showed a yield of 85.2%. Moreover, the infrared spectrum of the new compound is consistent with the standard infrared spectrum of divalproex sodium and has the following characterizing absorption bands: strong bands at 2960, 2873, 2935, 1694, 1569 and 1382 cm<sup>−</sup>
<sup>1</sup>. So the new compound was identified as divalproex sodium by its description, melting point and infrared spectrum.</p>
<p>Stock solutions of divalproex sodium were prepared in DMSO and freshly diluted to the desired concentrations before use. Final concentrations of DMSO in both control and treatment culture medium were identical in all studies, with a maximum level of 0.05%.</p>
</sec>
<sec id="section5-0960327112444477">
<title>Primary cultures of rat hepatocytes</title>
<p>From male rats, the hepatocytes were isolated by two-step collagenase reperfusion (Sprague-Dawley, 240–280 g), as described previously.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112444477">19</xref>
</sup> Briefly, after anesthesia, a catheter was inserted into the hepatic portal vein and the liver was perfused with D-Hank’s solution to remove the blood. Then the liver was again perfused with D-Hank’s solution including collagenase B and calcium chloride. The liver was removed and minced in D-Hank’s solution, and the cellular suspension obtained was then purified by filtration, centrifugation and washed with D-Hank’s solution. Monolayer hepatocytes were cultured at 37°C in a 5% CO<sub>2</sub> and 95% air atmosphere in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Cell viability was consistently above 90%, as determined via Trypan blue exclusion.</p>
</sec>
<sec id="section6-0960327112444477">
<title>Cell viability assay</title>
<p>The cell viability was assessed by a colorimetric MTT assay.<sup>
<xref ref-type="bibr" rid="bibr20-0960327112444477">20</xref>
</sup> The hepatocytes were plated in a 96-well plate for 24 h. The different concentrations of divalproex sodium (100, 300, 1000 and 3000 μM) were added to each well and were cultured for 24 h. The cells were cultured for another 4 h after adding 20 μl MTT (5 mg/ml). Then the culture medium was removed and 150 μl of DMSO was added to dissolve the dye crystal. The absorbance change was evaluated spectrophotometrically at 490 nm using a Multiskan Ascent microplate reader (BMG, Offenburg, Germany). Cell viability was expressed as the percentage of the absorbance of treated cells relative to the absorbance of DMSO control cells.</p>
</sec>
<sec id="section7-0960327112444477">
<title>LDH leakage assay</title>
<p>The release of LDH into the cell culture medium indicates cell membrane damage.<sup>
<xref ref-type="bibr" rid="bibr21-0960327112444477">21</xref>
</sup> After incubation with different concentrations of divalproex sodium (100, 300, 500 and 1000 μM) for 24 h, the culture medium was collected for the estimation of LDH leakage using the LDH assay kit (Jiancheng Bioengineering Co. Ltd, Nanjing, China), according to the manufacturer’s protocols. LDH leakage was measured on the basis of oxidation of reduced form of nicotinamide adenine dinucleotide (NADH) to NAD<sup>+</sup>, and the change in absorbance was read at 440 nm in an ultraviolet/visible scanning spectrophotometer (TianMei UV-8500, Shanghai, China).</p>
</sec>
<sec id="section8-0960327112444477">
<title>Assessment of ALT and AST activities</title>
<p>ALT and AST are two enzymes related with liver damage, as they are elevated in many liver diseases. The activities of ALT and AST were measured using a commercial kit by pyruvic acid method (Jiancheng Bioengineering Co. Ltd, Nanjing, China). After incubation with different concentrations of divalproex sodium (100, 300, 500 and 1000 μM) for 24 h, the culture medium was collected and the activities of ALT and AST were measured with automatic biochemistry analyzer (CL-7150, Hitachi, Tokyo).</p>
</sec>
<sec id="section9-0960327112444477">
<title>RNA extraction and quantitative real-time polymerase chain reaction</title>
<p>After incubation with different concentrations of divalproex sodium (25, 50, 100, 200 and 500 μM) for 24 h, total cellular RNA was isolated from hepatocytes using TRIzol reagent (Invitrogen, California, USA). Complementary DNA (cDNA) was synthesized from 1 μg of total RNA using SuperScript III First Strand cDNA Synthesis Kit (Invitrogen, California, USA) according to the manufacturer’s protocol. The real-time polymerase chain reaction (PCR) was performed on an Applied Biosystems Company 7900 real-time PCR system (PE Biosystems, Carlsbad, USA), using SYBR Green PCR Master Mix (Invitrogen, California, USA). The fold changes in the levels of SREBP-1c, ACC1, FAS, SCD1, PPARα, HMGCS2 and CPT1A were corrected by the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The 2<sup>−▵▵CT</sup> method was used to calculate the quantitation of relative gene expression as described by the manufacturer. The primers used for real-time PCR were listed in <xref ref-type="table" rid="table1-0960327112444477">Table 1</xref>.</p>
<table-wrap id="table1-0960327112444477" position="float">
<label>Table 1.</label>
<caption>
<p>Primers used for quantitative real-time polymerase chain reaction (PCR)</p>
</caption>
<graphic alternate-form-of="table1-0960327112444477" xlink:href="10.1177_0960327112444477-table1.tif"/>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5′–3′)</th>
<th>Reverse primer (5′–3′)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SREBP-1c</td>
<td>ATGGCGAACAGAATGTCCTC</td>
<td>GGGCCTGTGTCTCCTGTCT</td>
</tr>
<tr>
<td>ACC1</td>
<td>TGTGAACCTGAGAAATAGCA</td>
<td>GTGTTCAGAAGTGTGTGAGC</td>
</tr>
<tr>
<td>FAS</td>
<td>CACAGCATTCAGTCCTATCCACAGA</td>
<td>CACAGCCAACCAGATGCTTCA</td>
</tr>
<tr>
<td>SCD1</td>
<td>CCTCATCATTGCCAACACCAT</td>
<td>AGCCAACCCACGTGAGAGAA</td>
</tr>
<tr>
<td>PPARα</td>
<td>TTACCCTTGGAGATGAAGAG</td>
<td>GCAGGAAGTCTTAGAAGTGC</td>
</tr>
<tr>
<td>HMGCS2</td>
<td>CAGCTTACCGCAGGAAAATCC</td>
<td>CAAAAGGGTGTGTGGAAGATCA</td>
</tr>
<tr>
<td>CPT1A</td>
<td>CCACAAGGCTACAATGGGACAT</td>
<td>GAAGGAATGCAGGTCCACATC</td>
</tr>
<tr>
<td>GAPDH</td>
<td>AACATCATCCCTGCATCCAC</td>
<td>CTGCTTCACCACCTTCTTG</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112444477">
<p>ACC1: acetyl-CoA carboxylase 1; CPT1A: carnitine palmitoyltransferase 1A; FAS: fatty acid synthase; GADPH: glyceraldehyde-3-phosphate dehydrogenase; HMGCS2: 3-hydroxy-3-methylglutaryl-CoA synthase 2; PPARα: peroxisome proliferator-activated receptor α; SCD1: stearoyl-CoA desaturase 1; SREBP-1c: sterol regulatory element-binding protein 1c.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0960327112444477">
<title>Data analysis</title>
<p>Data were expressed as mean ± standard deviation. Statistical analysis was carried out using one-way analysis of variance followed by Dunnett’s test. The values of <italic>p</italic> &lt; 0.05 were considered statistically significant.</p>
</sec>
</sec>
<sec id="section11-0960327112444477">
<title>Results</title>
<sec id="section12-0960327112444477">
<title>Divalproex sodium decreased the viability of hepatocytes</title>
<p>To examine the effect of divalproex sodium on cell viability, the hepatocytes were treated with divalproex sodium for 24 h, the cell viability was assessed. As shown in <xref ref-type="fig" rid="fig1-0960327112444477">Figure 1</xref>, divalproex sodium decreased the viability of hepatocytes in a dose-dependent manner. There were statistically significant differences in cell viability between the divalproex sodium groups (300 μM divalproex sodium group, <italic>p</italic> &lt; 0.05; 1000 and 3000 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group.</p>
<fig id="fig1-0960327112444477" position="float">
<label>Figure 1.</label>
<caption>
<p>Divalproex sodium decreased the viability of hepatocytes. Hepatocytes were exposed to different concentrations of divalproex sodium (100, 300, 1000 and 3000 μM) for 24 h, cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Data were expressed as mean ± SD (<italic>n</italic> = 5). *<italic>p</italic> &lt; 0.05 and **<italic>p</italic> &lt; 0.01 compared with the dimethyl sulfoxide (DMSO) group.</p>
</caption>
<graphic alternate-form-of="fig1-0960327112444477" xlink:href="10.1177_0960327112444477-fig1.tif"/>
</fig>
</sec>
<sec id="section13-0960327112444477">
<title>Divalproex sodium increased LDH leakage</title>
<p>In order to investigate the effect of divalproex sodium on cell membrane integrity, the LDH level in the culture medium was measured. The results showed that divalproex sodium significantly increased LDH leakage in the culture medium of hepatocytes. There were statistically significant differences in LDH leakage between the divalproex sodium groups (100, 300, 500 and 1000 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group (<xref ref-type="fig" rid="fig2-0960327112444477">Figure 2</xref>).</p>
<fig id="fig2-0960327112444477" position="float">
<label>Figure 2.</label>
<caption>
<p>Divalproex sodium increased lactate dehydrogenase (LDH) leakage. The hepatocytes were exposed to different concentrations of divalproex sodium (100, 300, 500 and 1000 μM) for 24 h, the LDH leakage in culture medium was measured. Data were expressed as mean ± SD (<italic>n</italic> = 5). **<italic>p</italic> &lt; 0.01 compared with the dimethyl sulfoxide (DMSO) group.</p>
</caption>
<graphic alternate-form-of="fig2-0960327112444477" xlink:href="10.1177_0960327112444477-fig2.tif"/>
</fig>
</sec>
<sec id="section14-0960327112444477">
<title>Divalproex sodium increased the activities of ALT and AST</title>
<p>In order to further investigate the effects of divalproex sodium on liver enzymes, the activities of ALT and AST in hepatocytes were measured. The hepatocytes were treated with different concentrations of divalproex sodium for 24 h and the activities of ALT and AST in culture medium were measured. As shown in <xref ref-type="table" rid="table2-0960327112444477">Table 2</xref>, divalproex sodium increased significantly the activities of ALT and AST in hepatocytes in a dose-dependent manner. There were statistically significant differences in the activities of ALT and AST between the divalproex sodium groups (300 μM divalproex sodium group, <italic>p</italic> &lt; 0.05; 500 and 1000 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group.</p>
<table-wrap id="table2-0960327112444477" position="float">
<label>Table 2.</label>
<caption>
<p>Divalproex sodium increased the activities of ALT and AST in hepatocytes<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0960327112444477" xlink:href="10.1177_0960327112444477-table2.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>DMSO</th>
<th>100 μM</th>
<th>300 μM</th>
<th>500 μM</th>
<th>1000 μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (U/L)</td>
<td>11.32 ± 0.66</td>
<td>11.80 ± 0.57</td>
<td>13.10 ± 0.56<sup>b</sup>
</td>
<td>14.96 ± 1.20<sup>c</sup>
</td>
<td>15.48 ± 1.31<sup>c</sup>
</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>2.74 ± 0.43</td>
<td>3.04 ± 0.21</td>
<td>3.24 ± 0.11<sup>b</sup>
</td>
<td>4.08 ± 0.23<sup>c</sup>
</td>
<td>4.74 ± 0.15<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0960327112444477">
<p>ALT: alanine aminotransferase; AST: aspartate transaminase; DMSO: dimethyl sulfoxide.</p>
</fn>
<fn id="table-fn3-0960327112444477">
<p>
<sup>a</sup>Data were expressed as mean ± SD (<italic>n</italic>= 5).</p>
</fn>
<fn id="table-fn4-0960327112444477">
<p>
<sup>b</sup>
<italic>p</italic> &lt; 0.05 compared with the DMSO group.</p>
</fn>
<fn id="table-fn5-0960327112444477">
<p>
<sup>c</sup>
<italic>p</italic> &lt; 0.01 compared with the DMSO group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0960327112444477">
<title>Divalproex sodium increased the mRNA expressions of SREBP-1c and its downstream genes</title>
<p>To evaluate whether the hepatotoxicity induced by divalproex sodium was to activate the transcription factor SREBP-1c and its downstream genes, we measured the mRNA expressions of SREBP-1c, ACC1, FAS and SCD1 by real-time PCR. The results showed that the SREBP-1c mRNA expression was significantly increased in a dose-dependent manner (<xref ref-type="fig" rid="fig3-0960327112444477">Figure 3</xref>(a)). There were statistically significant differences in the mRNA expression of SREBP-1c between the divalproex sodium groups (100 μM divalproex sodium group, <italic>p</italic> &lt; 0.05; 200 and 500 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group. Moreover, these data also showed that divalproex sodium increased the mRNA expressions of ACC1, FAS and SCD1 about 2 times in 500 μM divalproex sodium group as compared to the DMSO group (<italic>p</italic> &lt; 0.01; <xref ref-type="fig" rid="fig3-0960327112444477">Figure 3</xref>(b), (c) and (d)).</p>
<fig id="fig3-0960327112444477" position="float">
<label>Figure 3.</label>
<caption>
<p>Divalproex sodium increased the expressions of sterol regulatory element-binding protein 1c (SREBP-1c) and its downstream genes acetyl-CoA carboxylase 1 (ACC1), fatty acid synthase (FAS) and stearoyl-CoA desaturase 1 (SCD1) in hepatocytes. The hepatocytes were exposed to different concentrations of divalproex sodium (25, 50, 100, 200 and 500 μM) for 24 h. The messenger RNA (mRNA) expressions were measured by real-time polymerase chain reaction (PCR). (a) Effect of divalproex sodium on SREBP-1c expression. (b) Effect of divalproex sodium on ACC1 expression. (c) Effect of divalproex sodium on FAS expression. (d) Effect of divalproex sodium on SCD1 expression. Data were expressed as mean ± SD (<italic>n</italic> = 3). *<italic>p</italic> &lt; 0.05 and **<italic>p</italic> &lt; 0.01 compared with the dimethyl sulfoxide (DMSO) group.</p>
</caption>
<graphic alternate-form-of="fig3-0960327112444477" xlink:href="10.1177_0960327112444477-fig3.tif"/>
</fig>
</sec>
<sec id="section16-0960327112444477">
<title>Divalproex sodium decreased the mRNA expressions of PPARα and its downstream genes</title>
<p>To further evaluate whether the hepatotoxicity induced by divalproex sodium was related with the transcription factor PPARα and its downstream genes, we measured the mRNA expressions of PPARα, HMGCS2 and CPT1A by real-time PCR. As a result, divalproex sodium decreased the mRNA expression of PPARα in a dose-dependent manner (<xref ref-type="fig" rid="fig4-0960327112444477">Figure 4</xref>(a)). There were statistically significant differences in the mRNA expression of PPARα between the divalproex sodium groups (50 μM divalproex sodium group, <italic>p</italic> &lt; 0.05; 100, 200 and 500 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group. Moreover, divalproex sodium decreased the mRNA expressions of HMGCS2 and CPT1A. There were statistically significant differences in the expressions of HMGCS2 and CPT1A between the divalproex sodium groups (100 μM divalproex sodium group, <italic>p</italic> &lt; 0.05; 200 and 500 μM divalproex sodium groups, <italic>p</italic> &lt; 0.01) and the DMSO group (<xref ref-type="fig" rid="fig4-0960327112444477">Figure 4</xref>(b) and (c)).</p>
<fig id="fig4-0960327112444477" position="float">
<label>Figure 4.</label>
<caption>
<p>Divalproex sodium decreased the expressions of peroxisome proliferator-activated receptor α (PPARα) and its downstream genes 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) and carnitine palmitoyltransferase 1A (CPT1A) in hepatocytes. The hepatocytes were exposed to different concentrations of divalproex sodium (25, 50, 100, 200 and 500 μM) for 24 h. The messenger RNA (mRNA) expressions were measured by real-time polymerase chain reaction (PCR). (a) Effect of divalproex sodium on PPARα expression. (b) Effect of divalproex sodium on HMGCS2 expression. (c) Effect of divalproex sodium on CPT1A expression. Data were expressed as mean ± SD (<italic>n</italic> = 3). *<italic>p</italic> &lt; 0.05 and **<italic>p</italic> &lt; 0.01 compared with the dimethyl sulfoxide (DMSO) group.</p>
</caption>
<graphic alternate-form-of="fig4-0960327112444477" xlink:href="10.1177_0960327112444477-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section17-0960327112444477">
<title>Discussion</title>
<p>Drug-induced hepatotoxicity is a major problem during drug development and the main cause for drug withdrawals from the market.<sup>
<xref ref-type="bibr" rid="bibr22-0960327112444477">22</xref>
</sup> Therefore, it is necessary to evaluate drug-induced hepatotoxicity for the design of safer therapeutic agents. Clinical studies have shown that divalproex sodium caused hepatic failure in patients accompanied by the abnormalities of hematology, serum chemistry and routine urinalysis. Even some patients progressed to fatal hepatotoxicity without developing any specific hepatic function abnormalities.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112444477">4</xref>
</sup> Although there have been numerous investigations into the mechanisms of hepatotoxicity of sodium valproate and valproic acid, the exact mechanism of hepatotoxicity induced by divalproex sodium was not clear. So it is very significant to explore divalproex sodium-induced hepatotoxicity and its potential mechanism. The cell viability, a marker of cytotoxicity, was decreased in divalproex sodium-treated hepatocytes in a dose-dependent manner in our present experiments. The LDH leakage is also a biomarker of cell integrity. LDH catalyzes the reversible oxidation of L-lactate to pyruvate; the increase in LDH leakage in hepatocytes confirms increased hepatocyte membrane permeability and cellular leakage.<sup>
<xref ref-type="bibr" rid="bibr23-0960327112444477">23</xref>
</sup> Clinical study confirmed that the LDH level in plasma was increased in patients treated with divalproex sodium.<sup>
<xref ref-type="bibr" rid="bibr23-0960327112444477">23</xref>,<xref ref-type="bibr" rid="bibr24-0960327112444477">24</xref>
</sup> Our results showed that divalproex sodium increased LDH leakage in hepatocytes. In previous experiments, we have observed that sodium valproate decreased the cell viability and increased LDH leakage in human hepatocellular liver carcinoma (HepG2) cells.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112444477">6</xref>
</sup> In addition, the increase in ALT and AST activities can be interpreted as evidence of hepatotoxicity. In the present study, we found that divalproex sodium significantly increased the activities of ALT and AST in hepatocytes in a dose-dependent manner. Clinical studies have also reported that divalproex sodium increased the activities of ALT and AST in patients.<sup>
<xref ref-type="bibr" rid="bibr25-0960327112444477">25</xref>,<xref ref-type="bibr" rid="bibr26-0960327112444477">26</xref>
</sup> In a previous study, we have observed sodium valproate increased the activities of ALT and AST in HepG2 cells.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112444477">6</xref>
</sup> Taken together, accumulating data suggest that divalproex sodium can result in the damage of hepatocytes and finally cause cell death.</p>
<p>It has been demonstrated that the transcription factors SREBPs and PPARs participate in fatty acid synthesis and degradation in liver, respectively.<sup>
<xref ref-type="bibr" rid="bibr27-0960327112444477">27</xref>
</sup> SREBP-1c is by far the most abundant isoform in liver and mainly regulates the expression of genes involved in fatty acid synthesis.<sup>
<xref ref-type="bibr" rid="bibr28-0960327112444477">28</xref>,<xref ref-type="bibr" rid="bibr29-0960327112444477">29</xref>
</sup> In the present study, we found that divalproex sodium increased the expression of SREBP-1c in hepatocytes. As well, the study showed that the antipsychotic drugs clozapine and haloperidol stimulated fatty acid synthesis through the activation of SREBP-1c.<sup>
<xref ref-type="bibr" rid="bibr30-0960327112444477">30</xref>
</sup> The enzymes of ACC1, FAS and SCD1 have been confirmed to participate in fatty acid synthesis regulated by SREBP-1c in liver. ACC1 is a biotin-containing enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, the rate-limiting step in fatty acid synthesis.<sup>
<xref ref-type="bibr" rid="bibr31-0960327112444477">31</xref>
</sup> The FAS plays an important role in lipogenesis of mammals through the synthesis of saturated long-chain fatty acids from acetyl-CoA and malonyl-CoA.<sup>
<xref ref-type="bibr" rid="bibr32-0960327112444477">32</xref>,<xref ref-type="bibr" rid="bibr33-0960327112444477">33</xref>
</sup> SCD1 is an enzyme responsible for the conversion of saturated fatty acid into monounsaturated fatty acids.<sup>
<xref ref-type="bibr" rid="bibr34-0960327112444477">34</xref>
</sup> Our present results demonstrated that divalproex sodium increased the mRNA expressions of ACC1, FAS and SCD1 in hepatocytes. It has been observed that the antipsychotic drugs clozapine and olanzapine strongly increased fatty acid synthesis by activating SREBP-1c and its associated downstream genes ACC1, FAS and SCD1 in rat hepatocytes.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112444477">14</xref>
</sup> The experiments also showed that the antipsychotics and antidepressants including haloperidol, olanzapine and mirtazapine induced hepatotoxicity by activating SREBP-1 and downstream genes HMGCS1 and SCD1 in cultured human liver cells.<sup>
<xref ref-type="bibr" rid="bibr35-0960327112444477">35</xref>
</sup> In addition, ethanol induced the hepatotoxicity by activating SREBP-1c and its downstream genes ACC and SCD1 involved in the synthesis of fatty acid in rats.<sup>
<xref ref-type="bibr" rid="bibr36-0960327112444477">36</xref>
</sup> Data from the present study suggest that the hepatotoxicity induced by divalproex sodium may be related with fatty acid synthesis mediated by SREBP-1c and its downstream genes ACC1, FAS and SCD1 in hepatocytes.</p>
<p>In addition to fatty acid synthesis mediated by SREBP-1c, the fatty acid degradation mediated by PPARα also plays a major role in drug-induced hepatotoxicity.<sup>
<xref ref-type="bibr" rid="bibr37-0960327112444477">37</xref>
</sup> In the present study, our data indicated that divalproex sodium decreased the expression of PPARα in hepatocytes. The antipsychotic drug including chlorpromazine, clozapine and ziprasidone were reported to decrease the fatty acid degradation by inhibiting PPARα in mice.<sup>
<xref ref-type="bibr" rid="bibr38-0960327112444477">38</xref>
</sup> Furthermore, PPARα regulates fatty acid degradation by activating its downstream genes HMGCS2 and CPT1A in liver. In fact, the activation of both HMGCS2 and CPT1A is a means of removing excess hepatic fatty acid.<sup>
<xref ref-type="bibr" rid="bibr39-0960327112444477">39</xref>,<xref ref-type="bibr" rid="bibr40-0960327112444477">40</xref>
</sup> The HMGCS2 gene is the most responsive to PPARα among its downstream genes. It is the first and rate-limiting enzyme in ketogenesis of liver.<sup>
<xref ref-type="bibr" rid="bibr41-0960327112444477">41</xref>
</sup> We further found that divalproex sodium decreased the expression of HMGCS2 in hepatocytes. And that, divalproex sodium decreased the expression of CPT1A in hepatocytes. CPT1A is the most abundant enzyme in liver. It catalyzes the esterification of acylcoenzyme A to carnitine, which is a key step in fatty acid oxidation.<sup>
<xref ref-type="bibr" rid="bibr42-0960327112444477">42</xref>,<xref ref-type="bibr" rid="bibr43-0960327112444477">43</xref>
</sup> As a matter of fact, the CPT1A is upregulated by PPARα in human liver.<sup>
<xref ref-type="bibr" rid="bibr44-0960327112444477">44</xref>
</sup> The antipsychotic drugs clozapine decreased the expressions of PPARα and its downstream gene acyl-CoA oxidase 1 in rat liver.<sup>
<xref ref-type="bibr" rid="bibr13-0960327112444477">13</xref>
</sup> Ethanol has been reported to cause acute liver damage by decreasing PPARα and its downstream genes medium chain acyl-CoA dehydrogenase and acyl-CoA oxidase expressions of liver tissues in mice.<sup>
<xref ref-type="bibr" rid="bibr45-0960327112444477">45</xref>
</sup> <italic>Euchresta horsfieldii</italic> Benn., which has been used for the traditional treatment of hyperlipidemia, increased the expressions of PPARα and its downstream genes HMGCS2 and CPT1A in human HepG2 cells.<sup>
<xref ref-type="bibr" rid="bibr46-0960327112444477">46</xref>
</sup> Overall, these findings indicate that the hepatotoxicity induced by divalproex sodium may be related with fatty acid degradation mediated by PPARα and its downstream genes HMGCS2 and CPT1A in hepatocytes.</p>
<p>In summary, the present study suggests that divalproex sodium can induce hepatotoxicity by decreasing cell viability and elevating the liver enzymes such as LDH, ALT and AST. Moreover, the hepatotoxicity induced by divalproex sodium may be related with both fatty acid synthesis mediated by SREBP-1c and fatty acid degradation mediated by PPARα. Studies are needed to measure the changes in these relevant proteins. Further studies are necessary to identify the exact mechanism of hepatoxicity induced by divalproex sodium.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112444477"><label>Funding</label>
<p>This study was supported by the National Natural Science Foundation of China (No. 81072643), Scientific and technological project of Xi’an city, Shaanxi Province (No. SF1028 (1)) and Doctoral Fund of Ministry of Education of China (No. 20090201110050).</p>
</fn>
<fn fn-type="conflict" id="fn2-0960327112444477"><label>Declaration of Conflict of Interest</label>
<p>The authors declared no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112444477">
<label>1.</label>
<citation citation-type="book">
<collab collab-type="author">Depakote<sup>®</sup> Tablet</collab>. <source>Physicians’ desk reference</source>. <publisher-loc>New Jersey</publisher-loc>: <publisher-name>Medical Economics Company</publisher-name>, <year>2002</year>.</citation>
</ref>
<ref id="bibr2-0960327112444477">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Macdonald</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>Antiepileptic drug mechanisms of action</article-title>. <source>Epilepsia</source> <year>1995</year>; <volume>36</volume>: <fpage>S2</fpage>–<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112444477">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freitag</surname>
<given-names>FG</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>HA</given-names>
</name>
<etal/>
</person-group> <article-title>A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis</article-title>. <source>Neurology</source> <year>2002</year>; <volume>58</volume>: <fpage>1652</fpage>–<lpage>1659</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112444477">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silberstein</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Wilmore</surname>
<given-names>LJ</given-names>
</name>
</person-group>. <article-title>Divalproex sodium: migraine treatment and monitoring</article-title>. <source>Headache</source> <year>1996</year>; <volume>36</volume>: <fpage>239</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112444477">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tessari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Coracina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cosma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tiengo</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hepatic lipid metabolism and non-alcoholic fatty liver disease</article-title>. <source>Nutr Metab Carbiovasc Dis</source> <year>2009</year>; <volume>19</volume>: <fpage>291</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112444477">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname>
<given-names>QL</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Participation of lipid transport and fatty acid metabolism in valproate sodium-induced hepatotoxicity in HepG2 cells</article-title>. <source>Toxicol Vitro</source> <year>2010</year>; <volume>24</volume>: <fpage>1086</fpage>–<lpage>1091</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112444477">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kersten</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Effects of fatty acids on gene expression: role of peroxisome proliferator-activated receptor alpha liver X receptor alpha and sterol regulatory element-binding protein-1c</article-title>. <source>Proc Nutr Soc</source> <year>2002</year>; <volume>61</volume>: <fpage>371</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112444477">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>TF</given-names>
</name>
</person-group>. <article-title>Sterol regulation of fatty-acid synthase promoter-coordinate feedback-regulation of two major lipid pathways</article-title>. <source>J Biol Chem</source> <year>1995</year>; <volume>270</volume>: <fpage>25578</fpage>–<lpage>25583</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112444477">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Spiegelman</surname>
<given-names>BM</given-names>
</name>
</person-group>. <article-title>ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism</article-title>. <source>Genes Dev</source> <year>1996</year>; <volume>10</volume>: <fpage>1096</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112444477">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Raalte</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Wasan</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future</article-title>. <source>Pharm Res</source> <year>2004</year>; <volume>21</volume>: <fpage>1531</fpage>–<lpage>1538</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112444477">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimano</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group> <article-title>Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling</article-title>. <source>Mol Endocrinol</source> <year>2003</year>; <volume>17</volume>: <fpage>1240</fpage>–<lpage>1254</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112444477">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kast-Woelbern</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Dana</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Cesario</surname>
<given-names>RM</given-names>
</name>
<etal/>
</person-group> <article-title>Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis</article-title>. <source>J Biol Chem</source> <year>2004</year>; <volume>279</volume>: <fpage>23908</fpage>–<lpage>23915</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112444477">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferno</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vik-Mo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jassim</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver</article-title>. <source>Psychopharmacology</source> <year>2009</year>; <volume>203</volume>: <fpage>73</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112444477">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lauressergues</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Staels</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Valeille</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes</article-title>. <source>Naunyn-Schmiedebergs Arch Pharmacol</source> <year>2010</year>; <volume>381</volume>: <fpage>427</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112444477">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voss</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>SP</given-names>
</name>
<etal/>
</person-group> <article-title>Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha</article-title>. <source>Toxicol Sci</source> <year>2006</year>; <volume>68</volume>: <fpage>108</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112444477">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giemsa</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kluge</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Eder</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Clofibrate causes an upregulation of PPAR-alpha target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source> <year>2007</year>; <volume>293</volume>: <fpage>R70</fpage>–<lpage>R77</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112444477">
<label>17.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name>
<surname>Meade</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>Sodium hydrogen divalproate oligomer</article-title>. <comment>US Patent 4988731</comment>, <year>1991</year>.</citation>
</ref>
<ref id="bibr18-0960327112444477">
<label>18.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name>
<surname>Meade</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>Sodium hydrogen divalproate oligomer</article-title>. <comment>US Patent 5212326</comment>, <year>1993</year>.</citation>
</ref>
<ref id="bibr19-0960327112444477">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seglen</surname>
<given-names>PO</given-names>
</name>
</person-group>. <article-title>Preparation of isolated rat liver cells</article-title>. <source>Methods Cell Biol</source> <year>1976</year>; <volume>13</volume>: <fpage>29</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112444477">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mosmann</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title>. <source>J Immunol Methods</source> <year>1983</year>; <volume>65</volume>: <fpage>55</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112444477">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legrand</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bour</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Lactate dehydrogenase (LDH) activity of the number of dead cells in the medium of cultured eukaryotic cells as marker</article-title>. <source>J Biotechnol</source> <year>1992</year>; <volume>25</volume>: <fpage>231</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112444477">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ostapowicz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YH</given-names>
</name>
</person-group>. <article-title>Acute hepatic failure: a Western perspective</article-title>. <source>J Gastroenterol Hepatol</source> <year>2000</year>; <volume>15</volume>: <fpage>480</fpage>–<lpage>488</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112444477">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bulle</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mavier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zafrani</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group> <article-title>Mechanism of gamma-glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat-a histochemical, biochemical and molecular approach</article-title>. <source>Hepatology</source> <year>1990</year>; <volume>11</volume>: <fpage>545</fpage>–<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112444477">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porsteinsson</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Tariot</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Erb</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Placebo-controlled study of divalproex sodium for agitation in dementia</article-title>. <source>Am J Geriatr Psychiatr</source> <year>2001</year>; <volume>9</volume>: <fpage>58</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112444477">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Henninger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>SB</given-names>
</name>
</person-group>. <article-title>Prevention of drug-induced liver toxicity</article-title>. <source>Gastroenterology</source> <year>2008</year>; <volume>134</volume>: <fpage>A822</fpage>–<lpage>A822</lpage>.</citation>
</ref>
<ref id="bibr26-0960327112444477">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redden</surname>
<given-names>L</given-names>
</name>
<name>
<surname>DelBello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>KD</given-names>
</name>
<etal/>
</person-group> <article-title>Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder</article-title>. <source>J Child Adolesc Psychopharmacol</source> <year>2009</year>; <volume>19</volume>: <fpage>83</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112444477">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuzaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shimano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yahagi</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPAR alpha</article-title>. <source>J Lipid Res</source> <year>2002</year>; <volume>43</volume>: <fpage>107</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112444477">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimano</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes</article-title>. <source>Prog Lipid Res</source> <year>2001</year>; <volume>40</volume>: <fpage>439</fpage>–<lpage>452</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112444477">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horton</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver</article-title>. <source>J Clin Invest</source> <year>2002</year>; <volume>109</volume>: <fpage>1125</fpage>–<lpage>1131</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112444477">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferno</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Raeder</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Vik-Mo</surname>
<given-names>AO</given-names>
</name>
<etal/>
</person-group> <article-title>Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?</article-title> <source>Pharmacogenomics J</source> <year>2005</year>; <volume>5</volume>: <fpage>298</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112444477">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harwood</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Petras</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Shelly</surname>
<given-names>LD</given-names>
</name>
<etal/>
</person-group> <article-title>Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals</article-title>. <source>J Biol Chem</source> <year>2003</year>; <volume>278</volume>: <fpage>37099</fpage>–<lpage>37111</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112444477">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakil</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Fatty acid synthase, a proficient multifunctional enzyme</article-title>. <source>Biochemistry</source> <year>1989</year>; <volume>28</volume>: <fpage>4523</fpage>–<lpage>4530</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112444477">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witkowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rangan</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Randhawa</surname>
<given-names>ZI</given-names>
</name>
<etal/>
</person-group> <article-title>Structural organization of the multifunctional animal fatty-acid synthase</article-title>. <source>FEBS J</source> <year>1991</year>; <volume>198</volume>: <fpage>571</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr34-0960327112444477">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ntambi</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Miyazaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dobrzyn</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Regulation of stearoyl-COA desaturase expression</article-title>. <source>Lipids</source> <year>2004</year>; <volume>39</volume>: <fpage>1061</fpage>–<lpage>1065</lpage>.</citation>
</ref>
<ref id="bibr35-0960327112444477">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raeder</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Ferno</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vik-Mo</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Steen</surname>
<given-names>VM</given-names>
</name>
</person-group>. <article-title>SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?</article-title> <source>Mol Cell Biochem</source> <year>2006</year>; <volume>289</volume>: <fpage>167</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr36-0960327112444477">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>HQ</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>YS</given-names>
</name>
<etal/>
</person-group> <article-title>Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes</article-title>. <source>Toxicol Appl Pharmacol</source> <year>2009</year>; <volume>236</volume>: <fpage>124</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr37-0960327112444477">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kersten</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Peroxisome proliferator-activated receptor alpha target genes</article-title>. <source>Cell Mol Life Sci</source> <year>2004</year>; <volume>61</volume>: <fpage>393</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr38-0960327112444477">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arulmozhi</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Dwyer</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Bodhankar</surname>
<given-names>SL</given-names>
</name>
</person-group>. <article-title>Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice</article-title>. <source>Life Sci</source> <year>2006</year>; <volume>79</volume>: <fpage>1865</fpage>–<lpage>1872</lpage>.</citation>
</ref>
<ref id="bibr39-0960327112444477">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LeMay</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pineau</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bigot</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Reduced hepatic fatty acid oxidation in fasting PPAR alpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression</article-title>. <source>FEBS Lett</source> <year>2000</year>; <volume>475</volume>: <fpage>163</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr40-0960327112444477">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGarry</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>NF</given-names>
</name>
</person-group>. <article-title>The mitochondrial carnitine palmitoyltransferase system-from concept to molecular analysis</article-title>. <source>FEBS J</source> <year>1997</year>; <volume>244</volume>: <fpage>1</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr41-0960327112444477">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>JugeAubry</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pernin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Favez</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements-Importance of the 5'-flanking region</article-title>. <source>J Biol Chem</source> <year>1997</year>; <volume>272</volume>: <fpage>25252</fpage>–<lpage>25259</lpage>.</citation>
</ref>
<ref id="bibr42-0960327112444477">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Britton</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1995</year>; <volume>92</volume>: <fpage>1984</fpage>–<lpage>1988</lpage>.</citation>
</ref>
<ref id="bibr43-0960327112444477">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Corstorphine</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Zammit</surname>
<given-names>VA</given-names>
</name>
</person-group>. <article-title>Topology of carnitine palmitoyltransferase I in the mitochondrial outer membrane</article-title>. <source>Biochem J</source> <year>1997</year>; <volume>323</volume>: <fpage>711</fpage>–<lpage>718</lpage>.</citation>
</ref>
<ref id="bibr44-0960327112444477">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mascaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Acosta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group> <article-title>Control of human muscle-type carnitine palmitoyltransferase I gene transcription by peroxisome proliferator-activated receptor</article-title>. <source>J Biol Chem</source> <year>1998</year>; <volume>273</volume>: <fpage>8560</fpage>–<lpage>8563</lpage>.</citation>
</ref>
<ref id="bibr45-0960327112444477">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Tectoridin, an isoflavone glycoside from the flower of <italic>Pueraria lobata</italic>, prevents acute ethanol-induced liver steatosis in mice</article-title>. <source>Toxicology</source> <year>2010</year>; <volume>276</volume>: <fpage>64</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr46-0960327112444477">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>
<italic>Euchresta horsfieldii</italic> Benn. activates peroxisome proliferator-activated receptor alpha and regulates expression of genes involved in fatty acid metabolism in human HepG2 cells</article-title>. <source>J Ethnopharmacol</source> <year>2011</year>; <volume>133</volume>: <fpage>244</fpage>–<lpage>247</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>